(MET) MetLife - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59156R1086

MET: Insurance, Annuities, Employee Benefits, Asset Management

MetLife, Inc. (NYSE: MET) is one of the largest financial services companies globally, specializing in insurance, annuities, employee benefits, and asset management. Incorporated in 1999 and headquartered in New York, the company operates across six distinct segments: Retirement and Income Solutions, Group Benefits, Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. This diversified structure allows MetLife to cater to a wide range of customers, from individuals to large corporations, across various geographic regions.

MetLife’s product portfolio is extensive, covering life, dental, disability, and accident insurance, as well as annuities and pension risk transfer solutions. The company also offers administrative services for employers, prepaid legal plans, and a variety of investment products tailored for institutional clients. Its services extend to structured settlements, longevity reinsurance, and credit insurance, making it a comprehensive provider in the life and health insurance space. Additionally, MetLife provides funding agreements and synthetic guaranteed interest contracts, which are critical for organizations looking to manage their financial obligations effectively.

From a financial standpoint, MetLife is a substantial player in the industry, with a market capitalization of approximately $56.7 billion. The company’s price-to-earnings (P/E) ratio stands at 13.43, with a forward P/E of 8.46, indicating expectations of future earnings growth. Its price-to-book (P/B) ratio of 2.07 reflects the market’s valuation of its assets and liabilities. The price-to-sales (P/S) ratio of 0.80 suggests that the company is reasonably valued relative to its revenue generation. These metrics are important for investors and fund managers assessing MetLife’s position in the life and health insurance sector.

MetLife’s global presence, diverse product offerings, and significant scale make it a key player in the insurance and financial services industry. Its ability to navigate different markets and provide tailored solutions positions it as a stable investment opportunity, particularly for those seeking exposure to the life and health insurance sector. For more information, visit their website at https://www.metlife.com.

Additional Sources for MET Stock

MET Stock Overview

Market Cap in USD 53,974m
Sector Financial Services
Industry Insurance - Life
GiC Sub-Industry Life & Health Insurance
IPO / Inception 2000-04-05

MET Stock Ratings

Growth 5y 87.2%
Fundamental 35.7%
Dividend 54.2%
Rel. Strength -7.08
Analysts 4.2/5
Fair Price Momentum 91.33 USD
Fair Price DCF 495.16 USD

MET Dividends

Dividend Yield 12m 2.77%
Yield on Cost 5y 9.30%
Annual Growth 5y 3.58%
Payout Consistency 34.6%

MET Growth Ratios

Growth Correlation 3m -19.5%
Growth Correlation 12m 82.2%
Growth Correlation 5y 86.1%
CAGR 5y 27.69%
CAGR/Max DD 5y 0.79
Sharpe Ratio 12m 1.69
Alpha 3.59
Beta 1.030
Volatility 20.37%
Current Volume 5392.3k
Average Volume 20d 3138.5k
What is the price of MET stocks?
As of April 01, 2025, the stock is trading at USD 80.29 with a total of 5,392,312 shares traded.
Over the past week, the price has changed by -4.62%, over one month by -6.83%, over three months by -1.31% and over the past year by +12.21%.
Is MetLife a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, MetLife (NYSE:MET) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 35.68 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MET as of April 2025 is 91.33. This means that MET is currently undervalued and has a potential upside of +13.75% (Margin of Safety).
Is MET a buy, sell or hold?
MetLife has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy MET.
  • Strong Buy: 7
  • Buy: 5
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0
What are the forecast for MET stock price target?
According to ValueRays Forecast Model, MET MetLife will be worth about 99.4 in April 2026. The stock is currently trading at 80.29. This means that the stock has a potential upside of +23.84%.
Issuer Forecast Upside
Wallstreet Target Price 95.9 19.4%
Analysts Target Price 94.4 17.5%
ValueRay Target Price 99.4 23.8%